Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight
Authors:
- 1 May 2017
- journal article
- review article
- Published by Elsevier in The Lancet Psychiatry
- Vol. 4 (5) , 419-426
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Paternalism, autonomy and reciprocity: ethical perspectives in encounters with patients in psychiatric in-patient careBMC Medical Ethics, 2013
- The Public Stigma of Mental IllnessJournal of Health and Social Behavior, 2013
- Treatment-resistant depression: therapeutic trends, challenges, and future directionsPatient Preference and Adherence, 2012
- To use or not to use: an update on licit and illicit ketamine useSubstance Abuse and Rehabilitation, 2011
- Ethical issues in deep brain stimulationFrontiers in Integrative Neuroscience, 2011
- Cognition and Depression: Current Status and Future DirectionsAnnual Review of Clinical Psychology, 2010
- The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic TreatmentsPharmaceuticals, 2010
- Consequences of chronic ketamine self‐administration upon neurocognitive function and psychological wellbeing: a 1‐year longitudinal studyAddiction, 2009
- Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant DepressionBiological Psychiatry, 2009
- Effects of Ketamine in Normal and Schizophrenic VolunteersNeuropsychopharmacology, 2001